Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists – the RIC-ICH study

BackgroundIntracranial hemorrhage (ICH) is a rare but serious side effect associated with the use of oral anticoagulants, such as dabigatran. The specific reversal agent for dabigatran, idarucizumab, is available for the management of individuals with ICH. The aim of this study was to provide real-w...

Full description

Bibliographic Details

Published in:	Frontiers in Neurology
Main Authors:	Nils Kuklik, Anika Hüsing, Andreas Stang, Marcus Brinkmann, Christoph C. Eschenfelder, Christian Weimar, Hans-Christoph Diener
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Subjects:	intracranial hemorrhage anticoagulation dabigatran idarucizumab vitamin-K-antagonists
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1212495/full